ID

29072

Description

Study ID: 101468/249 Clinical Study ID: 101468/249 Study Title: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00363857 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: N/A Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication: Restless Legs Syndrome; Restless Legs Syndrome (RLS)

Keywords

  1. 2/23/18 2/23/18 -
Copyright Holder

GlaxoSmithKline (GSK)

Uploaded on

February 23, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Clinical Study, Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS), Study ID: 101468/249, NCT00363857

Eligibility Check

  1. StudyEvent: ODM
    1. Eligibility Check
Please complete the following inclusion criteria.
Description

Please complete the following inclusion criteria.

Alias
UMLS CUI-1
C1512693
Patients diagnosed with RLS using International RLS Study Group (IRLSSG) diagnostic criteria
Description

RLS Diagnosis

Data type

boolean

Alias
UMLS CUI [1]
C0035258
Patients have had RLS symptoms with a history of a minimum of 15 nights of RLS symptoms during the previous month. In the case of a patient currently receiving medication for the treatment of RLS at the Screening visit this inclusion criteria can be waived. However, the patient must discontinue any previous medication for the treatment of RLS or sleep prior to the baseline visit (Day 0). The minimum discontinuation period is generally 5 half-lives of the medication or 7 consecutive nights medications free prior to baseline, whichever is the longer period.
Description

RLS Symptoms

Data type

boolean

Alias
UMLS CUI [1,1]
C1457887
UMLS CUI [1,2]
C0035258
Patients >18 years and <80 years of age.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
The patient must have given written informed consent prior to any specific study procedures.
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Please complete the following exclusion criteria.
Description

Please complete the following exclusion criteria.

Alias
UMLS CUI-1
C0680251
Patients suffering from RLS symptoms during the daytime (daytime defined as 10.00 until 18.00).
Description

RLS Symptoms

Data type

boolean

Alias
UMLS CUI [1,1]
C0035258
UMLS CUI [1,2]
C1457887
UMLS CUI [1,3]
C0332169
Patients who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (i.e. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).
Description

Sleep disorders

Data type

boolean

Alias
UMLS CUI [1]
C0851578
Patients suffering from movement disorders (i.e. Parkinson’s Disease, dyskinesias, and dystonias).
Description

Movement disorders

Data type

boolean

Alias
UMLS CUI [1]
C0026650
Patients who have medical conditions which could affect assessments of efficacy (i.e. diabetes, peripheral neuropathy, rheumatoid arthritis, or fibromyalgia syndrome).
Description

Comorbidity affecting efficacy

Data type

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0087111
Patients who have exhibited intolerance to ropinirole or any other dopamine agonist.
Description

Ropinirole intolerance

Data type

boolean

Alias
UMLS CUI [1,1]
C1744706
UMLS CUI [1,2]
C0244821
Patients who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within 6 months prior to screening.
Description

Substance abuse/dependence

Data type

boolean

Alias
UMLS CUI [1,1]
C0038586
UMLS CUI [1,2]
C0038580
Women of child-bearing potential who are not practicing a clinically accepted method of contraception such as oral contraception, surgical sterilisation, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant).
Description

Contraception

Data type

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C0332197
Women who have a positive pregnancy test or who are lactating.
Description

Pregnancy or breast feeding

Data type

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Patients who have clinically significant or unstable medical conditions which in the opinion of the investigator would render the patient unsuitable for the study (e.g., symptomatic orthostatic hypotension, severe cardiovascular disease, hepatic or renal failure, etc.).
Description

Unstable medical conditions

Data type

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0443343
Patients who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
Description

Compliance behavior

Data type

boolean

Alias
UMLS CUI [1,1]
C1321605
UMLS CUI [1,2]
C0439801
Patients with a diastolic blood pressure ≥110mmHg or ≤50mmHg OR systolic blood pressure ≥180mmHg or ≤90mmHg at screening or baseline.
Description

Blood pressure

Data type

boolean

Alias
UMLS CUI [1]
C0005823
Participation in any clinical drug or device trial in the three months prior to the baseline visit.
Description

Participation in other clinical trials

Data type

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C0008976

Similar models

Eligibility Check

  1. StudyEvent: ODM
    1. Eligibility Check
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Please complete the following inclusion criteria.
C1512693 (UMLS CUI-1)
RLS Diagnosis
Item
Patients diagnosed with RLS using International RLS Study Group (IRLSSG) diagnostic criteria
boolean
C0035258 (UMLS CUI [1])
RLS Symptoms
Item
Patients have had RLS symptoms with a history of a minimum of 15 nights of RLS symptoms during the previous month. In the case of a patient currently receiving medication for the treatment of RLS at the Screening visit this inclusion criteria can be waived. However, the patient must discontinue any previous medication for the treatment of RLS or sleep prior to the baseline visit (Day 0). The minimum discontinuation period is generally 5 half-lives of the medication or 7 consecutive nights medications free prior to baseline, whichever is the longer period.
boolean
C1457887 (UMLS CUI [1,1])
C0035258 (UMLS CUI [1,2])
Age
Item
Patients >18 years and <80 years of age.
boolean
C0001779 (UMLS CUI [1])
Informed consent
Item
The patient must have given written informed consent prior to any specific study procedures.
boolean
C0021430 (UMLS CUI [1])
Item Group
Please complete the following exclusion criteria.
C0680251 (UMLS CUI-1)
RLS Symptoms
Item
Patients suffering from RLS symptoms during the daytime (daytime defined as 10.00 until 18.00).
boolean
C0035258 (UMLS CUI [1,1])
C1457887 (UMLS CUI [1,2])
C0332169 (UMLS CUI [1,3])
Sleep disorders
Item
Patients who suffer from a primary sleep disorder other than RLS that may significantly affect the symptoms of RLS (i.e. narcolepsy, sleep terror disorder, sleepwalking disorder, breathing related sleep disorder).
boolean
C0851578 (UMLS CUI [1])
Movement disorders
Item
Patients suffering from movement disorders (i.e. Parkinson’s Disease, dyskinesias, and dystonias).
boolean
C0026650 (UMLS CUI [1])
Comorbidity affecting efficacy
Item
Patients who have medical conditions which could affect assessments of efficacy (i.e. diabetes, peripheral neuropathy, rheumatoid arthritis, or fibromyalgia syndrome).
boolean
C0009488 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
Ropinirole intolerance
Item
Patients who have exhibited intolerance to ropinirole or any other dopamine agonist.
boolean
C1744706 (UMLS CUI [1,1])
C0244821 (UMLS CUI [1,2])
Substance abuse/dependence
Item
Patients who meet DSM-IV criteria for substance abuse (alcohol or drugs) or substance dependence within 6 months prior to screening.
boolean
C0038586 (UMLS CUI [1,1])
C0038580 (UMLS CUI [1,2])
Contraception
Item
Women of child-bearing potential who are not practicing a clinically accepted method of contraception such as oral contraception, surgical sterilisation, IUD, diaphragm in conjunction with spermicidal foam and condom on the male partner, or systemic contraception (i.e., Norplant).
boolean
C0700589 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Pregnancy or breast feeding
Item
Women who have a positive pregnancy test or who are lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Unstable medical conditions
Item
Patients who have clinically significant or unstable medical conditions which in the opinion of the investigator would render the patient unsuitable for the study (e.g., symptomatic orthostatic hypotension, severe cardiovascular disease, hepatic or renal failure, etc.).
boolean
C3843040 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
Compliance behavior
Item
Patients who, in the opinion of the investigator, would be non-compliant with the visit schedule or other study procedures.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
Blood pressure
Item
Patients with a diastolic blood pressure ≥110mmHg or ≤50mmHg OR systolic blood pressure ≥180mmHg or ≤90mmHg at screening or baseline.
boolean
C0005823 (UMLS CUI [1])
Participation in other clinical trials
Item
Participation in any clinical drug or device trial in the three months prior to the baseline visit.
boolean
C2348568 (UMLS CUI [1,1])
C0008976 (UMLS CUI [1,2])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial